This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Plasma-Derived Drugs Market

Market Insights on Plasma-Derived Drugs covering sales outlook, demand forecast & up-to-date key trends

Plasma-Derived Drugs Market By Type (Albumin, Coagulation Factor, Immunoglobulin), Application (Hospitals, Clinics), End Use & Region - Forecast 2022-2032

Plasma-Derived Drugs Market Overview

The plasma-derived drugs market is poised to attain a CAGR of 6.5% during the forecast period, up from US$ 37 Bn in 2022 to reach a valuation of US$ 74 Bn by 2032.

Demand for plasma-derived drugs rises as plasma antibodies, immunoglobulins, clotting factors, fibrinogens, and other plasma-derived medicinal compounds can be extracted from plasma that has a wide range of applications and advantages.

Attributes 

Details 

Plasma Derived Drugs Market CAGR 

6.5%

Plasma Derived Drugs Market (2022)

US$ 37 Bn

Plasma Derived Drugs Market (2032) 

US$ 53 Bn 

Plasma-derived medicinal products (PDMPs) are used in medical treatment and prevention to treat autoimmune disorders and bleeding emergencies. Hence, the sales of plasma-derived drugs are expected to spike.

In addition, the demand for plasma-derived drugs can be attributed to chronic conditions like hemophilia, congenital and acquired immunodeficiencies, etc., which can also be treated with the aid of plasma-derived drugs.

Furthermore, increasing regulatory approvals for plasma-derived medicines are expected to drive the sales of plasma derived drugs during the forecast period.

For example, Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, announced in January 2022 that the National Medical Products Administration (NMPA) of China granted BPL a license to market ALBUMINEX 25 percent product in China.

Higher sales of plasma derived drugs can be attributed to key market players' increased adoption of inorganic strategies, such as agreements and collaborations.

The rise in the prevalence of rare and chronic diseases creates a more lucrative opportunity for market manufacturers to enlarge their plasma derived drugs market share

Immunoglobulin products, albumin products, clotting factors, and a few others are currently available in the plasma-derived drugs market that significantly aids in the treatment of various diseases, which in turn, scales up the sales of plasma derived drugs.

The rising demand for plasma derived drugs is also due to the unique mechanism associated with each plasma-derived drug and its usage to achieve better clinical outcomes.

Customize this Report

Let us know your requirement to get
100% FREE customization

What Factors are Shaping the Plasma-Derived Drugs Market Dynamics?

Demand for plasma derived drugs goes up as the cost of manufacturing plasma derived drugs is more than four times the cost of manufacturing other pharmaceuticals.

The business model for plasma-derived drugs is different than what is present in the pharmaceutical market. 

The clear-cut research process and drug discovery process is different; moreover, the industry requires a more vigorous approach to create a balance in the sales, thereby dwindling the sales of plasma derived drugs.

Manufacturers of plasma-derived drugs spend the majority of their resources on manufacturing each drug, and the same is making them give second thoughts, which may result in lower plasma derived drugs market share.

Sales of plasma derived drugs are lowered due to threats present in developing plasma-derived drugs.

Furthermore, threats of emerging pathogens greatly affect the production cost for each manufacturer in the plasma derived drugs market.

The manufacturing of plasma-derived drugs takes a significant time, it could go from eight months to more than twelve months, and any shortcomings during the period can create serious consequences for the company affecting the market dynamics. 

The same is considered as one of the factors adversely affecting the demand for plasma derived drugs as well as sales of plasma derived drugs during the forecast period.

The demand for plasma derived drugs is impacted by government policies that present to increase the number of blood banks.

Plasma policies aim to make the availability, and accessibility of plasma to a greater extent, and such aim significantly influences the sales of plasma derived drugs

Demand for plasma derived drugs surges on account of moving the available adequate amount of plasma throughout different corners for better.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What is the Regional Wise Outlook of the Plasma-Derived Drugs Market?

Geographically, the plasma derived drugs market is segmented into seven regions, viz. South Asia, East Asia, Europe, Latin America, North America, Oceania, and the Middle East and Africa. 

Each country is equally important to drive the demand for plasma derived drugs. Advanced or emerging healthcare settings help in restoring the market and increase the reach to a wider section of patients in need. 

Blood donation is an important part of the sales of plasma derived drugs. The greater number of blood units would result in a greater number of such products and hence, higher demand for plasma derived drugs.

The developed economies play an important role in the industry as well as the overall demand for plasma derived drugs, but emerging economies are also moving at a good pace. 

The North American region is estimated to have a significant plasma derived drugs market share, owing to its quality infrastructure supporting the need for plasma-derived drugs. 

They are followed by Europe, East Asia, and Oceania. The South Asia plasma-derived drugs market, would translate as a market exhibiting rising sales of plasma derived drugs.

The region’s market is expected to provide lucrative opportunities for industry experts, thereby enlarging their plasma derived drugs market share, coupled with a present change in adoption and growth in the general pharmaceutical market.

Who are a Few Notable Players in the Plasma Derived Drugs Market?

The key players involved in the market of plasma derived drugs include Grifols, S.A., Octa Pharma, Antaris Pharma, and CSL Limited. 

The present market structure of plasma-derived drugs is expected to change with efforts and research present in the clinical phase coupled with player’s effort to augment their plasma derived drugs market share.

Kamada Pharmaceuticals, China Biologic Products Holdings, Bio Products Laboratory Ltd., Inc., Shanghai RAAS, Kedrion, ADMA Biologics Inc., and Biotest AG are some other major players in the global plasma derived drugs market.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Scope of Report

Report Attribute 

Details

Growth rate 

CAGR of 6.5% from 2022 to 2032

Base year for estimation

2021

Historical data

2014 - 2020

Forecast period

2022 - 2032

Quantitative units

Revenue in USD billion, volume in kilotons, and CAGR from 2022 to 2032

Report coverage

Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis

Segments covered

Product, application, region

Regional scope

North America; Western Europe, Eastern Europe, Middle East, Africa, ASEAN, South Asia, Rest of Asia, Australia and New Zealand

Country scope

U.S.; Canada; Mexico; Germany; U.K.; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; UAE; Iran; South Africa

Key companies profiled

Kamada Pharmaceuticals, China Biologic Products Holdings, Bio Products Laboratory Ltd., Inc., Shanghai RAAS, Kedrion, ADMA Biologics Inc., and Biotest AG

Customization scope

Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs.

Frequently Asked Questions

The plasma derived drugs market is anticipated to record a CAGR of 6.5% during the forecast period.

The plasma derived drugs market size accounted for about US$ 33 Bn in 2019.

Grifols, S.A., Octa Pharma, Antaris Pharma, and CSL Limited. are some notable players in the plasma derived drugs market.

Table of Content

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Plasma-Derived Drugs Market